Edwards Q3 Sales Up 10.5% to $1.72B; Full-Year Guidance Raised Across TAVR, TMTT and EPS
EW sits 40% above its 52-week low of $74.66 on elevated volume (2.2× avg).
Summary
Edwards reported Q3 sales of $1.72 billion, up 10.5%, and adjusted EPS of $0.80, up 19%, then raised full-year guidance for sales growth, TAVR, TMTT and adjusted EPS. A $220.2 million impairment pushed GAAP EPS down to $0.53.
Key Events · Earnings and Guidance · EW
-
Q3 Sales Beat and Grow 10.5%
Net sales were $1,715.5 million versus $1,553.1 million a year ago, up 10.5% reported and 11.2% in constant currency. TAVR grew 8.0% to $1,241.6 million and TMTT grew 44.3% to $209.5 million.
-
Full-Year Guidance Raised on All Lines
Total company sales growth guidance rose to approximately 11.5% from 10% to 11%, TAVR to 9.0% to 9.5% from 8% to 9%, TMTT to $780 to $790 million from $760 to $780 million, and adjusted EPS to $2.97 to $3.05 from $2.95 to $3.05.
-
$220.2 Million Impairment Hits GAAP Earnings
GAAP operating income of $299.1 million included a $220.2 million impairment of an in-process research and development asset and fixed assets acquired in an acquisition. GAAP diluted EPS was $0.53 versus adjusted EPS of $0.80.
-
Q4 Outlook Set at $1.67B to $1.75B
For the fourth quarter of 2026 the company projects total sales of $1.67 to $1.75 billion and adjusted EPS of $0.61 to $0.69, with growth expected to come mainly from procedure volumes rather than share gains.
Analysis · EW · Industrial Applications And Services
Edwards beat its own bar and raised the full-year outlook on every line that matters: total sales growth to about 11.5% from 10-11%, TAVR to 9.0-9.5% from 8-9%, TMTT to $780-790 million from $760-780 million, and adjusted EPS to $2.97-$3.05. The quarter itself was solid — sales of $1.72 billion, up 10.5% reported and 11.2% in constant currency, with TMTT up 44.0% to $207 million and adjusted EPS of $0.80 up 19%. The catch is earnings quality: GAAP operating income of $299.1 million was cut by a $220.2 million impairment of an in-process research and development asset and fixed assets from an acquisition, so GAAP EPS was only $0.53 against $0.80 adjusted. Guidance going forward leans on procedure volume growth rather than share gains, which is a lower-risk assumption but also a lower-ceiling one. With the stock near its 52-week high, the raised outlook is the part that supports the multiple; the impairment is the part that reminds you acquisition spending has not all worked out.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EW was trading at $104.54 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $57.3B. The 52-week trading range was $74.66 to $100.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.